ICICI Prudential Asset Management Co Ltd Acquires Shares of 29,000 Zoetis Inc. $ZTS

ICICI Prudential Asset Management Co Ltd bought a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 29,000 shares of the company’s stock, valued at approximately $3,649,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Meiji Yasuda America Inc acquired a new position in shares of Zoetis during the 4th quarter worth $1,449,000. Hikari Tsushin Inc. grew its position in Zoetis by 295.8% in the fourth quarter. Hikari Tsushin Inc. now owns 164,238 shares of the company’s stock valued at $20,664,000 after acquiring an additional 122,744 shares during the last quarter. UniSuper Management Pty Ltd raised its stake in Zoetis by 205.3% during the fourth quarter. UniSuper Management Pty Ltd now owns 135,910 shares of the company’s stock worth $17,100,000 after acquiring an additional 91,390 shares in the last quarter. IFM Investors Pty Ltd raised its stake in Zoetis by 0.7% during the fourth quarter. IFM Investors Pty Ltd now owns 86,914 shares of the company’s stock worth $10,936,000 after acquiring an additional 630 shares in the last quarter. Finally, TCTC Holdings LLC lifted its holdings in shares of Zoetis by 1.3% in the fourth quarter. TCTC Holdings LLC now owns 40,519 shares of the company’s stock worth $5,098,000 after acquiring an additional 503 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
• Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
• Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
• Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by company insiders.

Zoetis Trading Up 0.3%

NYSE:ZTS opened at $81.51 on Friday. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $168.83. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm’s fifty day moving average is $97.70 and its 200-day moving average is $114.47. The firm has a market cap of $34.17 billion, a P/E ratio of 13.52, a P/E/G ratio of 1.27 and a beta of 0.75.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ZTS shares. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. UBS Group dropped their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. BTIG Research reaffirmed a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Finally, JPMorgan Chase & Co. cut their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $133.92.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.